



IPSOGEN
CANCER PROFILER

PRESS RELEASE

EHA 2011: IPSOGEN TO PRESENT ITS FIRST MULTICENTRE STUDY ON THE IS-MMR BCR-ABL ASSAY

Marseille, France, June 7, 2011 – IPSOGEN (Alternext: ALIPS) today announces that the results from a multicentre study on its IS-MMR BCR-ABL assay will be presented at the European Hematology Association (EHA) Annual Congress, that will take place June 9-12, 2011, in London, UK.

Quantification of BCR-ABL gene abnormality is a key biological tool oncologists use today to establish and monitor the optimal treatment regimen for Chronic Myelogenous Leukemia (CML) patients.

The IS-MMR BCR-ABL assay by IPSOGEN is calibrated against the BCR-ABL World Health Organization (WHO) Reference Panel, and BCR ABL results are directly expressed on the International Scale (IS).

This represents a major progress toward the accurate standardisation of BCR-ABL quantification.

The study, run in 14 European and US molecular laboratories, documents the added value of the IS-MMR BCR-ABL assay to convert results on the International Scale and ensure inter-laboratory standardisation.

Poster Presentation: Improvement of inter-laboratory standardization for BCR-ABL quantification with secondary reference material calibrated on the WHO Reference Panel (Abstract #133)

- **Lead Author:** F. Hermitte, Fr
- **June 10,** 17:45 - 19:00 hrs
- **Poster Session:** 'Chronic Myeloid Leukemia - Biology'

About BCR-ABL MbcR quantification in Chronic Myeloid Leukemia

The treatment of Chronic Myeloid Leukemia (CML) has been revolutionized by the discovery of tyrosine kinase inhibitors, specifically targeting leukemic cells carrying the BCR-ABL MbcR translocation. Although treatment results and outcomes vary among CML patients, many of them are in stable remission under TKI treatment and can have a « normal » life.

The quantification of BCR-ABL in peripheral blood samples has progressively become mandatory as a simple and reliable tool to evaluate response to treatment, and therefore monitor CML patients over time.

Standardization and accurate measurement of BCR-ABL transcripts across molecular laboratories is consequently of major importance for CML management, as clinicians take therapeutic decisions based on this parameter.

About BCR-ABL product range

The new BCR-ABL MbcR IS-MMR kit developed by IPSOGEN using WHO certified reference material enable the standardization and accurate measurement of BCR-ABL MbcR transcripts by RT-PCR.



IPSOGEN
CANCER PROFILER

PRESS RELEASE

With the use of an international reference calibrator, molecular laboratories directly obtain accurate BCR-ABL results calibrated on the WHO International Scale, therefore ensuring inter-laboratory testing harmonization.

The BCR-ABL product range is available in Europe and Rest of the World as CE – IVD marked kits, and as RUO kits in the US.

About IPSOGEN

IPSOGEN, cancer profiler, develops and markets molecular diagnostic tests that help to map diseases and guide patients and oncologists' decisions along their therapeutic path.

With more than 80 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now targeting breast cancer with the aim of providing currently inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN intends to become a world leader in the molecular profiling of cancers, and to continue the development and promotion of best-in-class diagnostic references that have a significant impact on patients, medical professionals and society.

The company headquartered in Marseille, France has a subsidiary in the USA.

For further information, visit www.ipsogen.com

Contacts

IPSOGEN

Vincent Fert

CEO

Tel : + 33 (0)4 9129 3090

fert@ipsogen.com

Fabienne Hermitte

R&D and Regulatory Affairs
Senior Director

Tel : + 33 (0)4 9129 3090

hermitte@ipsogen.com

Pascale Boissel

CFO

Tel : + 33 (0)4 9129 3090

pascale.boissel@ipsogen.com

ATCG Press

Corporate and Product
Information

Marielle Bricman

Tel : + 33 (0)4 9125 0785

ipsogen@atcg-partners.com

NewCap.

Financial communication and
Investor relations

Axelle Vuillermet & Pierre Laurent

Tel : + 33 (0)1 44 71 94 93

ipsogen@newcap.fr

ALIPS
LISTED
NYSE
ALTERNEXT